By: Armanda Dervishi, PharmD Candidate c\/o 2027<\/p>\n\n\n\n
Introduction<\/strong><\/p>\n\n\n\n Compounding has always been an important part of pharmacy practice. Patients often need medications that aren\u2019t available commercially \u2013 whether it\u2019s a dye-free suspension for a child, a topical cream, or hormone replacement therapy. However, in recent years, compounding has received more attention than ever before. In 2013, Congress enacted the Drug Quality and Security Act (DQSA), redefining federal oversight of compounding pharmacies in response to public safety concerns. Since then, both the FDA and state boards of pharmacy have worked to strengthen regulations but figuring out how to balance safety with patient access hasn\u2019t been easy.<\/p>\n\n\n\n FDA Oversight: 503A vs. 503B<\/strong><\/p>\n\n\n\n The DQSA created two main categories for compounding: 503A and 503B. Pharmacies that operate under 503A only prepare medications for individual patients when there is a prescription and remain under the oversight of state boards of pharmacy. On the other hand, 503B outsourcing facilities can produce larger batches for hospitals or clinics, but they must register with the FDA and adhere to stricter manufacturing standards, such as Current Good Manufacturing Practices (cGMP).1<\/sup> The FDA hoped this would provide a clearer system for oversight, but it also created some gray areas. Many small compounding pharmacies feel they are being held to the same standards as large manufacturers, which can be expensive and difficult to manage. At the same time, others argue that stronger oversight is necessary to ensure sterility and protect patients.1 <\/sup><\/p>\n\n\n\n The Mix of State Rules<\/strong><\/p>\n\n\n\n While the FDA sets broad rules, states still play a huge role. Every state board of pharmacy imposes its own requirements for personnel training, documentation, and facility standards. Some have quickly adopted USP <795>, <797>, and <800>, while others are behind.2 <\/sup>This inconsistency makes things complicated, especially for pharmacies that ship across state lines. A pharmacy might meet one state\u2019s requirements but fall short in another. It highlights why better collaboration between states and the FDA is needed \u2013 federal rules provide consistency, but local boards have the knowledge to enforce standards within their communities.3<\/sup><\/p>\n\n\n\n Politics and Legal Battles<\/strong><\/p>\n\n\n\n Compounding has also become a political issue. The FDA has been criticized for overreaching when it comes to restricting compounded products. Hormone therapies, veterinary compounding, and office use medications have all been points of conflict between regulators, providers, and patient advocates.4 <\/sup>Lawmakers are divided as well. Some support expanding FDA authority to protect public health, while others believe that too much regulation could limit access to therapies patients depend on. These debates reveal how challenging it is to strike the right balance between safety and accessibility.<\/p>\n\n\n\n Looking Ahead<\/strong><\/p>\n\n\n\n The future of compounding will likely be shaped by a few key developments:<\/p>\n\n\n\n Conclusion<\/strong><\/p>\n\n\n\n Compounding is at a pivotal point. Pharmacists recognize the importance of personalized medicine, but stricter regulations and higher standards are transforming the practice. Both the FDA and state boards aim to protect patients, yet their overlapping authority often confuses pharmacies caught in the middle. As the profession advances, pharmacists will need to not only uphold evolving standards but also advocate for fair regulations that ensure customized medications remain safe and accessible to the patients who need them most.<\/p>\n\n\n\n References<\/strong><\/p>\n\n\n\n <\/p>\n","protected":false},"excerpt":{"rendered":" By: Armanda Dervishi, PharmD Candidate c\/o 2027 Introduction Compounding has always been an important part of pharmacy practice. Patients often need medications that aren\u2019t available commercially \u2013 whether it\u2019s a dye-free suspension for a child, a topical cream, or hormone replacement therapy. However, in recent years, compounding has received more attention than ever before. In…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5,8],"tags":[],"class_list":["post-4188","post","type-post","status-publish","format-standard","hentry","category-news-politics","category-advice-opinions"],"views":42,"_links":{"self":[{"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/posts\/4188","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/comments?post=4188"}],"version-history":[{"count":1,"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/posts\/4188\/revisions"}],"predecessor-version":[{"id":4189,"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/posts\/4188\/revisions\/4189"}],"wp:attachment":[{"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/media?parent=4188"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/categories?post=4188"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/rhochistj.org\/RhoChiPost\/wp-json\/wp\/v2\/tags?post=4188"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}\n
\n